Kalpit Patel
Stock Analyst at Wolfe Research
(2.17)
# 2,886
Out of 5,246 analysts
78
Total ratings
43.4%
Success rate
-3.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Initiates: Peer Perform | n/a | $32.47 | - | 1 | May 19, 2026 | |
| CGON CG Oncology | Initiates: Peer Perform | n/a | $64.13 | - | 1 | May 19, 2026 | |
| MIRM Mirum Pharmaceuticals | Initiates: Outperform | $145 | $98.62 | +47.03% | 1 | May 19, 2026 | |
| GMAB Genmab | Initiates: Outperform | $32 | $26.88 | +19.07% | 1 | Mar 27, 2026 | |
| OLMA Olema Pharmaceuticals | Initiates: Peer Perform | n/a | $13.68 | - | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Initiates: Peer Perform | n/a | $299.45 | - | 1 | Mar 27, 2026 | |
| ONC BeOne Medicines AG | Initiates: Outperform | $340 | $310.25 | +9.59% | 1 | Mar 27, 2026 | |
| CORT Corcept Therapeutics | Upgrades: Peer Perform | n/a | $60.22 | - | 2 | Mar 26, 2026 | |
| AVBP ArriVent BioPharma | Maintains: Buy | $37 → $45 | $26.73 | +68.35% | 2 | Mar 23, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $78.89 | +48.31% | 6 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.20 | +150.00% | 6 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $8.32 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $14.52 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $20.24 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $16.62 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $48.13 | -12.74% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $151.56 | -50.51% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $138.23 | -20.42% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $5.96 | +101.34% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $4.55 | +207.69% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $29.01 | -17.27% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.28 | +173.44% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $4.24 | +112.26% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.22 | +136.97% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $11.35 | +252.42% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $2.47 | +21.46% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $17.24 | +16.01% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.04 | +642.57% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $19.94 | +80.54% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.67 | +5,289.22% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.00 | +800.00% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.24 | +303.23% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $10.87 | +819.96% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $21.55 | +248.11% | 2 | Sep 3, 2021 |
Tyra Biosciences
May 19, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $32.47
Upside: -
CG Oncology
May 19, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $64.13
Upside: -
Mirum Pharmaceuticals
May 19, 2026
Initiates: Outperform
Price Target: $145
Current: $98.62
Upside: +47.03%
Genmab
Mar 27, 2026
Initiates: Outperform
Price Target: $32
Current: $26.88
Upside: +19.07%
Olema Pharmaceuticals
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $13.68
Upside: -
Krystal Biotech
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $299.45
Upside: -
BeOne Medicines AG
Mar 27, 2026
Initiates: Outperform
Price Target: $340
Current: $310.25
Upside: +9.59%
Corcept Therapeutics
Mar 26, 2026
Upgrades: Peer Perform
Price Target: n/a
Current: $60.22
Upside: -
ArriVent BioPharma
Mar 23, 2026
Maintains: Buy
Price Target: $37 → $45
Current: $26.73
Upside: +68.35%
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $78.89
Upside: +48.31%
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.20
Upside: +150.00%
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $8.32
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $14.52
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $20.24
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $16.62
Upside: -
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $48.13
Upside: -12.74%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $151.56
Upside: -50.51%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $138.23
Upside: -20.42%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.96
Upside: +101.34%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $4.55
Upside: +207.69%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $29.01
Upside: -17.27%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.28
Upside: +173.44%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $4.24
Upside: +112.26%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.22
Upside: +136.97%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $11.35
Upside: +252.42%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $2.47
Upside: +21.46%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $17.24
Upside: +16.01%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.04
Upside: +642.57%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $19.94
Upside: +80.54%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.67
Upside: +5,289.22%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.00
Upside: +800.00%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.24
Upside: +303.23%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $10.87
Upside: +819.96%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $21.55
Upside: +248.11%